Clinical features and diagnostic imaging of cholangiolocellular carcinoma compared with other primary liver cancers: a surgical perspective.


Journal

Technology in cancer research & treatment
ISSN: 1533-0338
Titre abrégé: Technol Cancer Res Treat
Pays: United States
ID NLM: 101140941

Informations de publication

Date de publication:
Historique:
entrez: 19 10 2020
pubmed: 20 10 2020
medline: 25 11 2021
Statut: ppublish

Résumé

Although cholangiolocellular carcinoma is considered a combined hepatocellular and cholangiocarcinoma, we feel that this classification is not appropriate. Therefore, we compared the diagnostic imaging findings, surgical prognosis, and pathological features of cholangiolocellular carcinoma with those of other combined hepatocellular and cholangiocarcinoma subtypes, hepatocellular carcinoma, and cholangiocarcinoma. The study patients included 7 with classical type combined hepatocellular and cholangiocarcinoma; 8 with stem cell feature, intermediate type combined hepatocellular and cholangiocarcinoma; 13 with cholangiolocellular carcinoma; 58 with cholangiocarcinoma; and 359 with hepatocellular carcinoma. All patients underwent hepatectomy or living-related donor liver transplantation from 2001 to 2014. cholangiolocellular carcinoma could be distinguished from hepatocellular carcinom, other combined hepatocellular and cholangiocarcinoma subtypes, and cholangiocarcinoma by the presence of intratumoral Glisson's pedicle, hepatic vein penetration, and tumor-staining pattern on angiography-assisted CT. Cholangiolocellular carcinoma was associated with a significantly lower SUV-max than that of cholangiocarcinoma on FDG-PET. Hepatocellular carcinoma, classical type, and cholangiolocellular carcinoma had significantly better prognoses than stem cell feature, intermediate type and cholangiocarcinoma. A cholangiocarcinoma component was detected in cholangiolocellular carcinoma that progressed to the hepatic hilum, and the cholangiocarcinoma component was found in perineural invasion and lymph node metastases. From the viewpoint of surgeon, cholangiolocellular carcinoma should be classified as a good-prognosis subtype of biliary tract carcinoma because of its tendency to differentiate into cholangiocarcinoma during its progression, and its distinctive imaging and few recurrence rates different from other combined hepatocellular and cholangiocarcinoma subtypes.

Sections du résumé

BACKGROUND AND OBJECTIVES
Although cholangiolocellular carcinoma is considered a combined hepatocellular and cholangiocarcinoma, we feel that this classification is not appropriate. Therefore, we compared the diagnostic imaging findings, surgical prognosis, and pathological features of cholangiolocellular carcinoma with those of other combined hepatocellular and cholangiocarcinoma subtypes, hepatocellular carcinoma, and cholangiocarcinoma.
METHODS
The study patients included 7 with classical type combined hepatocellular and cholangiocarcinoma; 8 with stem cell feature, intermediate type combined hepatocellular and cholangiocarcinoma; 13 with cholangiolocellular carcinoma; 58 with cholangiocarcinoma; and 359 with hepatocellular carcinoma. All patients underwent hepatectomy or living-related donor liver transplantation from 2001 to 2014.
RESULTS
cholangiolocellular carcinoma could be distinguished from hepatocellular carcinom, other combined hepatocellular and cholangiocarcinoma subtypes, and cholangiocarcinoma by the presence of intratumoral Glisson's pedicle, hepatic vein penetration, and tumor-staining pattern on angiography-assisted CT. Cholangiolocellular carcinoma was associated with a significantly lower SUV-max than that of cholangiocarcinoma on FDG-PET. Hepatocellular carcinoma, classical type, and cholangiolocellular carcinoma had significantly better prognoses than stem cell feature, intermediate type and cholangiocarcinoma. A cholangiocarcinoma component was detected in cholangiolocellular carcinoma that progressed to the hepatic hilum, and the cholangiocarcinoma component was found in perineural invasion and lymph node metastases.
CONCLUSIONS
From the viewpoint of surgeon, cholangiolocellular carcinoma should be classified as a good-prognosis subtype of biliary tract carcinoma because of its tendency to differentiate into cholangiocarcinoma during its progression, and its distinctive imaging and few recurrence rates different from other combined hepatocellular and cholangiocarcinoma subtypes.

Identifiants

pubmed: 33073719
doi: 10.1177/1533033820948141
pmc: PMC7592326
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1533033820948141

Références

World J Surg. 2017 May;41(5):1347-1357
pubmed: 27896409
Histopathology. 2017 Feb;70(3):423-434
pubmed: 27634656
Ann Surg Oncol. 2014 Jun;21 Suppl 3:S451-8
pubmed: 24633664
Hepatology. 2008 May;47(5):1544-56
pubmed: 18393293
Hepatology. 2018 Jul;68(1):113-126
pubmed: 29360137
Ann Transplant. 2017 Feb 28;22:115-120
pubmed: 28242867
Abdom Radiol (NY). 2017 Mar;42(3):861-869
pubmed: 27747442
Prog Histochem Cytochem. 2007;42(2):61-110
pubmed: 17616258
Intern Med. 2017 Nov 15;56(22):3027-3031
pubmed: 28943569
Hum Pathol. 2008 Aug;39(8):1185-96
pubmed: 18547618
Cancer Res. 2017 Nov 15;77(22):6131-6143
pubmed: 28951464
Am J Surg Pathol. 2016 May;40(5):608-16
pubmed: 26735856
J Hepatol. 2017 May;66(5):952-961
pubmed: 28126467
Am J Surg Pathol. 2014 Mar;38(3):364-9
pubmed: 24487593
Histopathology. 2007 Sep;51(3):390-400
pubmed: 17553067
Hepatology. 1996 Nov;24(5):1074-8
pubmed: 8903378
Am J Surg Pathol. 2013 Apr;37(4):496-505
pubmed: 23388123
Liver Int. 2015 Mar;35(3):1024-35
pubmed: 24712771
Cancer. 1959 Jul-Aug;12(4):753-9
pubmed: 13663020
Am J Clin Pathol. 1998 Mar;109(3):302-8
pubmed: 9495202
J Gastroenterol Hepatol. 2001 Dec;16(12):1402-8
pubmed: 11851840

Auteurs

Hiroyuki Takamura (H)

General and Digestive Surgery, 12857Kanazawa Medical University, Kahoku, Ishikawa, Japan.
Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Ryousuke Gabata (R)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Yoshinao Obatake (Y)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Shinichi Nakanuma (S)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Hironori Hayashi (H)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Kazuto Kozaka (K)

Radiology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Motoko Sasaki (M)

Pathology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Mitsuyoshi Okazaki (M)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Takahisa Yamaguchi (T)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Hiroyuki Shimbashi (H)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Shiro Terai (S)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Koichi Okamoto (K)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Isamu Makino (I)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Jun Kinoshita (J)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Keishi Nakamura (K)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Tomoharu Miyashita (T)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Hidehiro Tajima (H)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Itasu Ninomiya (I)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Sachio Fushida (S)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Azusa Kitao (A)

Radiology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Masaaki Kitahara (M)

Gastroenterology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Kuniaki Arai (K)

Gastroenterology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Taro Yamashita (T)

Gastroenterology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Tatsuya Yamashita (T)

Gastroenterology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Hiroko Ikeda (H)

Pathology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Yasunori Satoh (Y)

Pathology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Kenichi Harada (K)

Pathology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Syuichi Kaneko (S)

Gastroenterology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Toshihumi Gabata (T)

Radiology, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Tateo Kosaka (T)

General and Digestive Surgery, 12857Kanazawa Medical University, Kahoku, Ishikawa, Japan.

Tetsuo Ohta (T)

Gastroenterologic Surgery, 12858Kanazawa University, Kanazawa, Ishikawa, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH